Legal & General Group
TERN

Legal & General Group’s Terns Pharmaceuticals TERN Stock Holding History

Legal & General Group’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.46M Buy
46,691
+28,633
+159% +$1.18M ﹤0.01% 1825
2025
Q4 		$730K Buy
18,058
+11,834
+190% +$273K ﹤0.01% 2308
2025
Q3 		$46.7K Sell
6,224
-541
-8% -$3.45K ﹤0.01% 2748
2025
Q2 		$25.2K Buy
6,765
+454
+7% +$1.42K ﹤0.01% 2912
2025
Q1 		$17.4K Hold
6,311
– – ﹤0.01% 2989
2024
Q4 		$35K Buy
6,311
+1,234
+24% +$8.36K ﹤0.01% 2848
2024
Q3 		$42.3K Buy
5,077
+23
+0.5% +$189 ﹤0.01% 2815
2024
Q2 		$34.4K Sell
5,054
-22,479
-82% -$136K ﹤0.01% 2855
2024
Q1 		$181K Sell
27,533
-89
-0.3% -$581 ﹤0.01% 2691
2023
Q4 		$179K Hold
27,622
– – ﹤0.01% 2716
2023
Q3 		$139K Buy
27,622
+2,021
+8% +$12.8K ﹤0.01% 2788
2023
Q2 		$224K Buy
+25,601
New +$298K ﹤0.01% 2711
2022
Q2 		– Sell
-1,454
Closed -$4K – 3651
2022
Q1 		$4K Buy
1,454
+175
+14% +$747 ﹤0.01% 3522
2021
Q4 		$9K Hold
1,279
– – ﹤0.01% 3478
2021
Q3 		$13K Buy
1,279
+400
+46% +$4.15K ﹤0.01% 3404
2021
Q2 		$11K Hold
879
– – ﹤0.01% 3413
2021
Q1 		$19K Buy
+879
New +$19.3K ﹤0.01% 3154

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Legal & General Group's TERN Position: Q1 2026 in Review

Legal & General Group increased its Terns Pharmaceuticals (TERN) stake by 159% in Q1 2026, buying an estimated $1.18M and bringing the position to 46,691 shares worth $2.46M. The position accounts for ﹤0.01% of the portfolio, ranked #1825.

Legal & General Group first reported a position in TERN in Q1 2021 and has held it in 17 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Legal & General Group held 46,691 shares of Terns Pharmaceuticals worth $2.46M as of Q1 2026.
  • Legal & General Group bought 28,633 Terns Pharmaceuticals shares in Q1 2026, an estimated $1.18M.
  • Terns Pharmaceuticals made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #1825 holding.
  • Legal & General Group first reported a position in Terns Pharmaceuticals in Q1 2021 and has held it in 17 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.